- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilar Articles for the Week of December 13
Here are the top 5 biosimilar articles for the week of December 13, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of December 13, 2021.
Number 5: Tot Biopharm received China regulatory approval for a bevacizumab biosimilar and Fujifilm moves forward with plans for an Innovation and Collaboration Center.
Number 4: In midterm results for a phase 2 study presented at the the 2021 San Antonio Breast Cancer Symposium (SABCS), a trastuzumab biosimilar in conjunction with gedatolisib demonstrated an overall response rate of 58.8% with manageable toxicity in patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (mBC).
Number 3: Researchers who surveyed patients and oncologists about biosimilars and switches to biosimilars from reference products found discrepancies between patients’ perceptions and physician perceptions of whether the information provided was adequate.
Number 2: Ahead of sales and revenues, Icelandic company Alvotech lined up a massive capital investment and an initial public offering (IPO).
Number 1: Long-term survival findings for the trastuzumab biosimilar Ontruzant demonstrated equivalence to the reference product (Herceptin) in a phase 3 study of patients with HER2–positive breast cancer, investigators reported at the 2021 SABCS.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
The Top 5 Most-Read Ophthalmology Articles of 2024
December 30th 2024The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective treatments for retinal conditions like neovascular age-related macular degeneration, although patent disputes pose challenges to their market entry and adoption.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
The Top 5 Most-Read Policy Articles of 2024
December 28th 2024The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.
